ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax of $79.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax · last filed 2025-02-19
- ELI LILLY AND COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, before tax for fiscal 2024 was $79.30M, a 27.58% decline from fiscal 2023.
- ELI LILLY AND COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, before tax for fiscal 2023 was $109.50M, a 74.71% decline from fiscal 2022.
- ELI LILLY AND COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, before tax for fiscal 2022 was $432.90M, a 185.55% increase from fiscal 2021.
- ELI LILLY AND COMPANY other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, before tax for fiscal 2021 was $151.60M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax 12 month |
|---|---|
| 2024-12-31 | $79.30M 10-K · filed 2025-02-19 |
| 2023-12-31 | $109.50M 10-K · filed 2025-02-19 |
| 2022-12-31 | $432.90M 10-K · filed 2025-02-19 |
| 2021-12-31 | $151.60M 10-K · filed 2024-02-21 |
| 2020-12-31 | -$152.90M 10-K · filed 2023-02-22 |
| 2019-12-31 | $34.30M 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |